SkinBioTherapeutics plc
LSE:SBTX

Jigglypop Analysis For SkinBioTherapeutics plc 🤓

SkinBioTherapeutics trades at 19.4p, roughly mid‑range between its 52‑week low of 12p and high of 27.5p, and above its 50‑ and 200‑day averages. A 46% one‑month surge and a £50m micro‑cap profile point to momentum rather than mispricing. Recent updates showed higher revenue and narrowing losses, with FY2026 growth guided, plus ongoing consolidation and a Croda tie‑up in skincare. However, leadership churn (COO exit, new CFO) and a pipeline heavy in early‑stage microbiome assets keep execution risk elevated. Net: this screens as speculative, not a classic value play; the discount to the 52‑week peak offers upside if delivery continues, but volatility around milestones and governance changes remains high. Near term sentiment: cautiously constructive, driven by newsflow into the AGM period.

About SkinBioTherapeutics plc 👋

SkinBioTherapeutics plc is a life sciences company focused on researching, developing, and commercializing microbiome-based technologies for human health in the United Kingdom, the United States, Europe, and beyond. Its programs include SkinBiotix, which leverages the microbiome to support wound healing and reduce infection risk; AxisBiotix-Ps, aimed at easing psoriasis-related symptoms; and early-stage platforms MediBiotix, CleanBiotix, and PharmaBiotix. The company has a collaboration with Croda Plc to develop SkinBiotix as an active ingredient for the skincare and cosmetics industry. It serves the cosmetic skincare, food supplement, medical dermatology, infection control, and pharmaceutical skincare markets. Formerly known as Skinbiotix Ltd, it changed its name to SkinBioTherapeutics plc in December 2016. Incorporated in 2015, the company is headquartered in Newcastle upon Tyne, United Kingdom.